Browse > Article
http://dx.doi.org/10.3857/roj.2018.00164

Clinical outcome of proton therapy for patients with chordomas  

Youn, Sang Hee (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Cho, Kwan Ho (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Kim, Joo-Young (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Ha, Boram (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Lim, Young Kyung (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Jeong, Jong Hwi (Proton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Center)
Lee, Sang Hyun (Department of Radiology, National Cancer Center Research Institute and Hospital, National Cancer Center)
Yoo, Heon (Neuro-Oncology Clinic, National Cancer Center Research Institute and Hospital, National Cancer Center)
Gwak, Ho-Shin (Neuro-Oncology Clinic, National Cancer Center Research Institute and Hospital, National Cancer Center)
Shin, Sang Hoon (Neuro-Oncology Clinic, National Cancer Center Research Institute and Hospital, National Cancer Center)
Hong, Eun Kyung (Department of Pathology, National Cancer Center Research Institute and Hospital, National Cancer Center)
Kim, Han Kyu (Department of Neurosurgery, Bundang CHA Medical Center, CHA University College of Medicine)
Hong, Je Beom (Department of Neurosurgery, Bundang CHA Medical Center, CHA University College of Medicine)
Publication Information
Radiation Oncology Journal / v.36, no.3, 2018 , pp. 182-191 More about this Journal
Abstract
Purpose: To investigate the clinical outcome of proton therapy (PT) in patients with chordoma. Materials and Methods: Fifty-eight patients with chordoma treated with PT between June 2007 and December 2015 at the National Cancer Center, Korea, were retrospectively analyzed. The median total dose was 69.6 cobalt gray equivalent (CGE; range, 64.8 to 79.2 CGE). Local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and disease-specific survival (DSS) rates were calculated by the Kaplan-Meier method. Results: With the median follow-up of 42.8 months (range, 4 to 174 months), the 5-year LPFS, DMFS, OS, and DSS rates were 87.9%, 86.7%, 88.3%, and 92.9%, respectively. The tumor location was associated with the patterns of failure: the LPFS rates were lower for cervical tumors (57.1%) than for non-cervical tumors (93.1%) (p = 0.02), and the DMFS rates were lower for sacral tumors (53.5%) than for non-sacral tumors (100%) (p = 0.001). The total dose was associated with both the LPFS rate and DMFS rate. The initial tumor size was associated with the DMFS rate, but was not associated with the LPFS rate. Three patients had grade 3 late toxicity with none ≥grade 4. Conclusion: PT is an effective and safe treatment in patients with chordomas. The tumor location was associated with the patterns of failure: local failure was common in cervical tumors, and distant failure was common in sacral tumors. Further refinement of PT, such as the utilization of intensity modulated PT for cervical tumors, is warranted to improve the outcome.
Keywords
Chordoma; Proton therapy; Treatment outcome; Complications;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol 2012;13:e69-76.
2 Ahmed R, Sheybani A, Menezes AH, Buatti JM, Hitchon PW. Disease outcomes for skull base and spinal chordomas: a single center experience. Clin Neurol Neurosurg 2015;130:67-73.
3 Di Maio S, Yip S, Al Zhrani GA, et al. Novel targeted therapies in chordoma: an update. Ther Clin Risk Manag 2015;11:873-83.
4 DeLaney TF, Liebsch NJ, Pedlow FX, et al. Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 2014;110:115-22.
5 Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH. Chordoma: the nonsarcoma primary bone tumor. Oncologist 2007;12:1344-50.
6 Kim YJ, Cho KH, Lim YK, et al. The volumetric change and dose-response relationship following hypofractionated proton therapy for chordomas. Acta Oncol 2014;53:563-8.
7 Catton C, O'Sullivan B, Bell R, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol 1996;41:67-72.
8 Cummings BJ, Hodson DI, Bush RS. Chordoma: the results of megavoltage radiation therapy. Int J Radiat Oncol Biol Phys 1983;9:633-42.
9 Indelicato DJ, Rotondo RL, Begosh-Mayne D, et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys 2016;95:297-303.
10 Grosshans DR, Zhu XR, Melancon A, et al. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes. Int J Radiat Oncol Biol Phys 2014;90:540-6.
11 Yasuda M, Bresson D, Chibbaro S, et al. Chordomas of the skull base and cervical spine: clinical outcomes associated with a multimodal surgical resection combined with proton-beam radiation in 40 patients. Neurosurg Rev 2012;35:171-83.
12 Rotondo RL, Folkert W, Liebsch NJ, et al. High-dose protonbased radiation therapy in the management of spine chordomas: outcomes and clinicopathological prognostic factors. J Neurosurg Spine 2015;23:788-97.
13 Stieb S, Snider JW 3rd, Placidi L, et al. Long-term clinical safety of high-dose proton radiation therapy delivered with pencil beam scanning technique for extracranial chordomas and chondrosarcomas in adult patients: clinical evidence of spinal cord tolerance. Int J Radiat Oncol Biol Phys 2018;100:218-25.
14 Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 1997;24:103-10.
15 Terahara A, Niemierko A, Goitein M, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. Int J Radiat Oncol Biol Phys 1999;45:351-8.
16 Forsyth PA, Cascino TL, Shaw EG, et al. Intracranial chordomas: a clinicopathological and prognostic study of 51 cases. J Neurosurg 1993;78:741-7.
17 Staab A, Rutz HP, Ares C, et al. Spot-scanning-based proton therapy for extracranial chordoma. Int J Radiat Oncol Biol Phys 2011;81:e489-96.
18 McDonald MW, Linton OR, Moore MG, Ting JY, Cohen- Gadol AA, Shah MV. Influence of residual tumor volume and radiation dose coverage in outcomes for clival chordoma. Int J Radiat Oncol Biol Phys 2016;95:304-11.
19 Radaelli S, Stacchiotti S, Ruggieri P, et al. Sacral chordoma: long-term outcome of a large series of patients surgically treated at two reference centers. Spine (Phila Pa 1976) 2016;41:1049-57.